Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05824390 Active, not recruiting - IgA Nephropathy Clinical Trials

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

Start date: June 20, 2020
Phase: Phase 4
Study type: Interventional

A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.

NCT ID: NCT05534919 Active, not recruiting - Clinical trials for Primary Immunoglobulin A Nephropathy (IgAN)

Efficacy and Safety in Chinese Patients With Immunoglobulin A Nephropathy (IgAN) Who Have Completed Study Nef-301

Start date: December 9, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in Chinese patients who have completed Nef-301 and continue to be treated with a stable dose of Renin-angiotensin system (RAS) inhibitor therapy (Angiotensin-converting enzyme inhibitors (ACEIs) and/or Angiotensin II type I receptor blockers (ARBs).

NCT ID: NCT05248646 Active, not recruiting - Clinical trials for Immunoglobulin A Nephropathy

Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)

Start date: March 15, 2022
Phase: Phase 3
Study type: Interventional

This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy.

NCT ID: NCT04663204 Active, not recruiting - Kidney Diseases Clinical Trials

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

SPARTAN
Start date: December 10, 2020
Phase: Phase 2
Study type: Interventional

To determine the nephroprotective potential of treatment with sparsentan in patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy.

NCT ID: NCT04578834 Active, not recruiting - IgA Nephropathy Clinical Trials

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

APPLAUSE-IgAN
Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

NCT ID: NCT04573920 Active, not recruiting - Clinical trials for Diabetic Kidney Disease

Atrasentan in Patients With Proteinuric Glomerular Diseases

AFFINITY
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

NCT ID: NCT04573478 Active, not recruiting - IgA Nephropathy Clinical Trials

Atrasentan in Patients With IgA Nephropathy

ALIGN
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

NCT ID: NCT04541043 Active, not recruiting - Clinical trials for Primary IgA Nephropathy

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

Nefigard-OLE
Start date: November 14, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.

NCT ID: NCT03945318 Active, not recruiting - IgA Nephropathy Clinical Trials

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Start date: April 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).

NCT ID: NCT03762850 Active, not recruiting - Clinical trials for Immunoglobulin A Nephropathy

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

PROTECT
Start date: December 11, 2018
Phase: Phase 3
Study type: Interventional

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).